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went allogeneic HCT in SGH between January 2005 and
December 2010, with at least one year follow-up, was carried
out for the pre-implementation phase. Patients who under-
went allogeneic and autologous HCT between May 2012 and
February 2013, with at least six months follow-up were
reviewed for the post-implementation phase. Primary
endpoint was the overall vaccination rate. Secondary end-
points included the time to ﬁrst vaccination and infection
rate.
Results: Eighty-one evaluable patients were included in the
pre-implementation phase, of whom, 41 did not receive any
vaccination. In the post-implementation phase, among the
39 evaluable patients, only 9 did not receive any vaccination.
Among those vaccinated, median time to ﬁrst vaccination
was 20 (range, 4-72) months post-HCT in the pre-imple-
mentation phase versus 6 (range, 4-13) months post-HCT in
the post-implementation phase. Overall vaccination rate at
various time-points was 3.4% and 59.3% for the pre- and
post-implementation group, respectively (p<0.05). Inﬂuenza
infection occurred in 18 (22.2%) patients pre-implementa-
tion as compared to 3 (7.7%) post-implementation. Of note,
these infections occurred in patients who did not receive
inﬂuenza vaccine.
Conclusions: The vaccination chart detailing the required
vaccines at various time-points post-HCT proved to be a
useful aid in facilitating timely prescribing and accurate
tracking of vaccination status. Timely administration of
required vaccines may result in reduced infectious compli-
cations. Importance of more effective strategies to further
improve vaccination rates in this high risk population is
underscored.458
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Background: Plerixafor (Mozobil) has been approved for use
in multiple myeloma (MM) and non-Hodgkin lymphoma
(NHL) patients (pts) in combination with G-CSF to mobilize
hematopoetic stem cells (CD34) in collection for autologous
transplant (tx). Many different mobilization approaches exist
in this ﬁeld, and we evaluate the role of Plerixafor in MM and
amyloidosis (AL) pts.
Methods: To evaluate plerixafor mobilization in the trans-
plant setting, all MM and AL patients whoweremobilized for
autologous stem cell transplant (autoSCT) between 2010 and
2012 were included. Sufﬁcient CD34+ cell collection was
deﬁned both using a minimal cutpoint of 2x106 as well as an
optimal goal of 5x106 CD34 cells. Signiﬁcant inﬂuences on
the ability to achieve these collection goals on day 1 and
across all collections were evaluated using univariate logistic
regression models in addition to graphical analyses and two
sample tests. In addition to clinical characteristics, weassessed the impact of plerixafor mobilization use and also
lenalidomide and thalidomide use on these outcomes.
Results: Overall, 196 pts (10 AL, 182 MM, 4 MM/AL) were
mobilized for autoSCTs from 2010-2012. Most pts were male
(60%), most were Caucasian (88%), and the median age at
transplant was 59 years (range: 18 to 73). About half of pts
(52%) received lenalidomide (lena), and only 5% received
thalidomide prior to mobilization; the median number of
lena cycles was 4 (range: 1 to 11). Comorbidity indices were
similar to those who did vs. did not receive plerixafor
(p¼0.8). On day 1 collections, 154 pts achieved a yield of
>2x106 and 87 pts>5x106 CD34+ cells. Across all collections,
all but 2 pts had a total yield of at least 2 million CD34 cells,
and 152 had at least 5x106 CD34 cells. Several factors
appeared to inﬂuence a pts ability to achieve a yield of
>5x106 CD34+ cells: age (OR¼0.94, p¼0.014), day 1 yield of
>2x106 CD34+ cells (OR¼14.5, p<0.0001), and the total
number of collections (OR¼0.32, p<0.0001). Days to ANC
recovery after transplant was also borderline associated with
a total yield of at least 5x106 CD34+ cells (OR¼0.82,
p¼0.075). While lena use was not signiﬁcantly associated
with total yield of 5 million CD34+ cells, pts who had prior
lenawere less likely to achieve a yield of at least 2x106 CD34+
cells on day 1 collection vs. those who did not (OR¼0.48,
p¼0.045). Prior radiation therapy was not signiﬁcantly
associated with any of the collection goal metrics. Plerixafor
use was not signiﬁcantly associated with the ability to ach-
ieve a yield of 5x106 CD34+ cells on day 1 or in total; how-
ever, plerixafor use was signiﬁcantly associated with not
achieving a day 1 collection of at least 2x106 CD34+ cells
(OR¼0.24, p¼0.0007); however, this is likely due more to the
decision algorithms used to determine administration of
plerixafor for mobilization prior to autoSCT than a statement
on the effectiveness of plerixafor as a mobilizing agent.459
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Background: Melphalan at a dose of 200 mg/m2 IV (MEL
200) is considered the standard preparative regimen for
autologous hematopoietic stem cell transplantation (auto-
HCT) for multiple myeloma. However, reduced doses of
melphalan such as140 mg/m2 IV (MEL 140) are often used in
older patients or patients with renal dysfunction.
Methods: The purpose of this retrospective analysis was to
determine if there was a difference in toxicity, treatment-
related mortality (TRM), response rate, progression- free
survival (PFS) or overall survival (OS) in patients that
received 140 mg/m2 of melphalan (MEL 140) compared to
those receiving MEL 200 for auto-HCT. From June 1, 1996
through December 31, 2012, 63 patients received MEL 140.
We compared their outcomes with 252 patients that
received MEL 200.
